REGIONAL COMMITTEE FOR THE EASTERN MEDITERRANEAN

Thirty-ninth Session

Agenda item 13

MANAGEMENT ADVISORY COMMITTEE (MAC)
OF THE ACTION PROGRAMME ON ESSENTIAL DRUGS - NOMINATION OF A MEMBER STATE FROM THE EMR
Introduction

The WHO Action Programme on Essential Drugs (DAP) was established in 1981 "to collaborate with countries in ensuring the regular supply at the lowest possible cost and the rational use of a selected number of safe and effective drugs and vaccines of acceptable quality".

Two committees, with different terms of reference, are currently involved in matters related to management of the Programme: the Committee on Drug Policies and the Management Advisory Committee (MAC).

MAC represents the interests and responsibilities of WHO's external partners collaborating with WHO in its Action Programme on Essential Drugs. It acts as an advisory body to the Director-General of WHO, making recommendations on matters related to policy, strategy, finance, management, monitoring and evaluation of the Programme.

Operation

MAC meets once a year, and concentrates on reviewing the Programme for that year based on financial support pledged, as well as past, present and future coordination of external support, development work and operational research. The meeting also reviews and guides the next year's programme and related budget. MAC may also meet more frequently, upon request of either its chairperson or the Director-General of WHO, and with the latter's agreement. The Programme Manager of DAP is also the Secretary of MAC.

Composition

- Member States that contributed funding in support of DAP's general budget in the previous fiscal year, or provided bilateral support to developing countries for the formulation or implementation of national drug policies, in conformity with WHO's policies on essential drugs;

- Two Member States from each of WHO's six regions selected by their respective regional committees for a three-year term from among those Member States with which DAP is collaborating;

- The four major international organizations collaborating in the implementation of WHO's Revised Strategy on Drugs (RSD), namely: UNDP, UNICEF, UNIDO and the World Bank; and
The chairperson or the vice-chairperson of the Committee on Drug Policies of the Executive Board, or a member designated by the chairperson.

With respect to regional representation, MAC has to adopt a system of "staggered" change of membership to achieve a three year cycle in which four out of the 12 regional members would be replaced each year.

In 1990, the Regional Committee selected two members from the EMR, the Syrian Arab Republic for three years and Tunisia for two years, for membership on the Management Advisory Committee (MAC) of the Action Programme on Essential Drugs. The membership of Tunisia will, therefore, expire in 1992.

Accordingly, the Regional Committee can select in 1992 one Member State from the EMR for a three-year membership on the Management Advisory Committee of the Action Programme on Essential Drugs. It is worth mentioning that the Terms of Reference of the MAC allow that members selected from the six WHO regions may be reappointed.

At present, DAP is funding large Essential Drugs projects in Sudan and Yemen.

It is expected that DAP will support some activities in other countries. These include Djibouti, Egypt, the Islamic Republic of Iran, the Syrian Arab Republic and Tunisia.
Agenda item 13

MANAGEMENT ADVISORY COMMITTEE (MAC) OF THE ACTION PROGRAMME ON ESSENTIAL DRUGS – NOMINATION OF A MEMBER STATE FROM THE EASTERN MEDITERRANEAN REGION

Introductory Paragraph

We now come to Agenda item 13 dealing with the nomination of one Member State from the Eastern Mediterranean Region to the Management Advisory Committee (MAC) of the Action Programme on Essential Drugs.

The members are aware of the WHO Action Programme on Essential Drugs (DAP). The Programme was established in 1981 "to collaborate with countries in ensuring the regular supply at the lowest possible cost and the rational use of a selected number of safe and effective drugs and vaccines of acceptable quality".

At present, DAP is funding large essential drugs projects in Sudan and Yemen.

Two committees, with different terms of reference, are currently involved in matters related to management of the Programme: the Committee on Drug Policies and the Management Advisory Committee (MAC).

MAC represents the interests and responsibilities of WHO's external partners collaborating with WHO in its Action Programme on Essential Drugs. It acts as an advisory body to the Director-General of WHO, making recommendations on matters related to policy, strategy, finance, management, monitoring and evaluation of the Programme.

With respect to regional representation, MAC agreed to adopt a system of "staggered" change of membership to achieve a three year cycle in which four out of the 12 regional members would be replaced each year.
Accordingly, the Regional Committee is to nominate one member from the Eastern Mediterranean Region for a three-year membership in the Management Advisory Committee (MAC) of the Action Programme on Essential Drugs, to replace Tunisia whose membership will expire in 1992. It is worth mentioning that the Terms of Reference of the MAC do allow that members selected from the six WHO regions may be reappointed.
NOMINATION OF A MEMBER STATE FROM THE EASTERN MEDITERRANEAN REGION TO THE MANAGEMENT ADVISORY COMMITTEE OF THE ACTION PROGRAMME ON ESSENTIAL DRUGS

The Regional Committee nominates [Name] for a period of three years from 1 January 1993 to 31 December 1996 for membership in the Management Advisory Committee of the Action Programme on Essential Drugs.